BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis

Nature Communications

Volumn 7, Issue , 2016, Pages

  Richart, Laia ^a   Carrillo De Santa Pau, Enrique ^a   Río Machín, Ana ^a   De Andrés, Mónica P ^a   Cigudosa, Juan C ^a   Lobo, Víctor J Sánchez Arévalo ^a   Real, Francisco X ^a,b  

^a Centro Nacional de Investigations Oncológicas   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODOMAIN PHD TRANSCRIPTION FACTOR; DNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CELL NUCLEUS ANTIGEN; FETAL ALZHEIMER ANTIGEN; MYC PROTEIN; MYC PROTEIN, HUMAN; MYC PROTEIN, MOUSE; NERVE PROTEIN;

APOPTOSIS; BIOACTIVITY; BIOINFORMATICS; CANCER; DISEASE TREATMENT; DNA; GENETIC ANALYSIS; TUMOR;

ACINAR CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DNA DAMAGE CHECKPOINT; EMBRYO; FIBROBLAST; GENE INACTIVATION; GENE INTERACTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; NULL ALLELE; ONCOGENE C MYC; PANCREAS ADENOCARCINOMA; PRECANCER; PROTEIN DNA BINDING; TRANSCRIPTION INITIATION; ANIMAL; CELL LINE; FACTUAL DATABASE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; KNOCKOUT MOUSE; METABOLISM; PANCREAS TUMOR;

ANIMALS; ANTIGENS, NUCLEAR; CARCINOGENESIS; CELL LINE; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DATABASES, FACTUAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION FACTORS;

EID: 84953235679     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10153     Document Type: Article

References (75)

1. Vita, M. & Henriksson, M. The Myc oncoprotein as a therapeutic target for human cancer. Semin. Cancer Biol. 16, 318-330 (2006).
2. Tansey, W. P. Mammalian MYC proteins and cancer. New J. Sci. 2014, 1-27 (2014).
3. Blackwood, E. M. & Eisenman, R. N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251, 1211-1217 (1991).
4. Blackwell, T. K. et al. Binding of Myc proteins to canonical and noncanonical DNA sequences. Mol. Cell Biol. 13, 5216-5224 (1993).
5. Fernandez, P. C. et al. Genomic targets of the human c-Myc protein. Genes Dev. 17, 1115-1129 (2003).
6. Guccione, E. et al. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat. Cell Biol. 8, 764-770 (2006).
7. Sabò, A. et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 511, 488-492 (2014).
8. Cheng, S. W. et al. c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat. Genet. 22, 102-105 (1999).
9. Rahl, P. B. et al. c-Myc regulates transcriptional pause release. Cell 141, 432-445 (2010).
10. Thomas, L. R. et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol. Cell 58, 440-452 (2015).
11. Langst, G. et al. Nucleosome movement by CHRAC and ISWI without disruption or trans-displacement of the histone octamer. Cell 97, 843-852 (1999).
12. Xiao, H. et al. Dual functions of largest NURF subunit NURF301 in nucleosome sliding and transcription factor interactions. Mol. Cell 8, 531-543 (2001).
13. Vicent, G. P. et al. Four enzymes cooperate to displace histone H1 during the first minute of hormonal gene activation. Genes Dev. 25, 845-862 (2011).
14. Alkhatib, S. G. & Landry, J. W. The nucleosome remodeling factor. FEBS Lett. 585, 3197-3207 (2011).
15. Balbás-Martínez, C. et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat. Genet. 45, 1464-1469 (2013).
16. Landry, J. et al. Essential role of chromatin remodeling protein Bptf in early mouse embryos and embryonic stem cells. PLoS Genet. 4, e1000241 (2008).
17. Neri, F. et al. Myc regulates the transcription of the PRC2 gene to control the expression of developmental genes in embryonic stem cells. Mol. Cell. Biol. 32, 840-851 (2012).
18. Lovén, J. et al. Revisiting global gene expression analysis. Cell 151, 476-482 (2012).
19. Schuhmacher, M. et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. 29, 397-406 (2001).
20. Schlosser, I. et al. Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line. Oncogene 24, 520-524 (2005).
21. Acosta, J. C. et al. Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest. Mol. Cell. Biol. 28, 7286-7295 (2008).
22. Kim, Y. H. et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 25, 130-138 (2006).
23. O'Donnell et al. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol. Cell. Biol. 26, 2373-2386 (2006).
24. Frank, S. R. et al. MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep. 4, 575-580 (2003).
25. Nagy, Z. & Tora, L. Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene 26, 5341-5357 (2007).
26. Perna, D. et al. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblast. Oncogene 31, 1695-1709 (2012).
27. Bailey, T. L. et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res. 37, W202-W208 (2009).
28. Di Stefano, B. et al. C/EBPa poises B cells for rapid reprogramming into induced pluripotent stem cells. Nature 506, 235-239 (2014).
29. Thurman, R. E. et al. The accessible chromatin landscape of the human genome. Nature 489, 75-82 (2012).
30. Liu, Y. C. et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS ONE 3, e2722 (2008).
31. Dominguez-Sola, D. et al. Non-transcriptional control of DNA replication by c-Myc. Nature 448, 445-451 (2007).
32. Murga, M. et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat. Struct. Biol. 18, 1331-1335 (2011).
33. Evan, G. I. et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119-128 (1992).
34. Taub, R. et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl Acad. Sci. USA 79, 7837-7841 (1982).
35. Sansom, O. J. et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 446, 676-679 (2007).
36. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
37. Garson, J. A. et al. N-myc gene expression and oncoprotein characterization in medulloblastoma. Br. J. Cancer 59, 889-894 (1989).
38. Wu, R. et al. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. Am. J. Pathol. 162, 1603-1610 (2003).
39. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
40. Martinelli, P. et al. Gata6 is required for complete acinar differentiation and maintenance of the exocrine pancreas in adult mice. Gut 62, 1481-1488 (2013).
41. Flandez, M. et al. Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRas(G12V)-driven pancreatic tumourigenesis. Gut 63, 647-655 (2014).
42. Sandgren, E. P. et al. Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc. Natl Acad. Sci. USA 88, 93-97 (1991).
43. Aguilar, S. et al. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumours and contribution to cancer progression. Am. J. Pathol. 165, 1129-1139 (2004).
44. Kress, T. R. et al. MYC: connecting selective transcriptional control to global RNA production. Nat. Rev. Cancer. 15, 593-607 (2015).
45. Wysocka, J. et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442, 86-90 (2006).
46. Martinato, F. et al. Analysis of Myc induced histone modifications on target chromatin. PloS One 3, e3650 (2008).
47. Carré, C. et al. The Drosophila NURF remodelling and the ATAC histone acetylase complexes functionally interact and are required for global chromosome organization. EMBO Rep. 9, 187-192 (2008).
48. Hill, D. A. & Imbalzano, A. N. Human SWI/SNF nucleosome remodeling activity is partially inhibited by linker histone H1. Biochemistry 39, 11649-11656 (2000).
49. Qiu, Z. et al. Functional interactions between NURF and Ctcf regulate gene expression. Mol. Cell. Biol. 35, 224-237 (2015).
50. Heintzman, N. D. et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39, 311-318 (2007).
51. Krebs, A. R. et al. SAGA and ATAC histone acetyl transferase complexes regulate distinct sets of genes and ATAC defines a class of p300-independent enhancers. Mol. Cell 44, 410-423 (2011).
52. Smallwood, A. & Ren, B. Genome organization and long-range regulation of gene expression by enhancers. Curr. Opin. Cell Biol. 25, 387-394 (2013).
53. Ruthenburg, A. J. et al. Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions. Cell 145, 692-706 (2011).
54. Schnetz, M. P. et al. CHD7 targets active gene enhancer elements to modulate ES cell-specific gene ex-pression. PLoS Genet. 6, pe1001023 (2010).
55. Rada-Iglesias, A. et al. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470, 279-283 (2011).
56. Soucek, L. et al. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res. 62, 3507-3510 (2002).
57. Savino, M. et al. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One 6, e22284 (2011).
58. Hoffman, B. & Liebermann, D. A. Apoptotic signaling by c-MYC. Oncogene 27, 6462-6472 (2008).
59. Nesbit, C. E., Tersak, J. M. & Prochownik, E. V. MYC oncogenes and human neoplastic disease. Oncogene 18, 3004-3016 (1999).
60. Schwab, M., Varmus, H. E. & Bishop, J. M. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature 316, 160-162 (1985).
61. Malynn, B. A. et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev. 14, 1390-1399 (2000).
62. Stanton, B. R. et al. Loss of N-myc function results in embryonic lethality and failure of the epi- thelial component of the embryo to develop. Genes Dev. 6, 2235-2247 (1992).
63. Gombert, W. M. & Krumm, A. Targeted deletion of multiple CTCF-binding elements in the human C-MYC gene reveals a requirement for CTCF in C-MYC expression. PLoS One 4, e6109 (2009).
64. Prochownik, E. V. & Vogt, P. K. Therapeutic targeting of Myc. Genes Cancer 1, 650-659 (2010).
65. Arvanitis, C. & Felsher, D. W. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin. Cancer Biol. 16, 313-317 (2006).
66. Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501 (2015).
67. Saborowski, M. et al. A modular and flexible ESC-based mouse model of pancreatic cancer. Genes Dev. 28, 85-97 (2014).
68. Dawson, M. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533 (2011).
69. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011).
70. Jones, M. H., Hamana, N. & Shimane, M. Identification and characterization of BPTF, a novel bromodomain transcription factor. Genomics 63, 35-39 (2000).
71. Kawaguchi, Y. et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat Genet. 32, 128-34 (2002).
72. Burlison, J. S. et al. Pdx-1 and Ptf1a concurrently determine fate specification of pancreatic multipotent progenitor cells. Dev. Biol. 316, 74-86 (2008).
73. Ye, T. et al. seqMINER: an integrated ChIP-seq data interpretation platform. Nucleic. Acids. Res. 39, e35 (2010).
74. Lovén, J. et al. Revisiting global gene expression analysis. Cell 151, 476-82 (2012).
75. Seitz, V. et al. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PLoS One 6, e26837 (2011).